Anti-fatigue agent

Patent metadata

Field	Value
Publication number	US-9609884-B2
Application number	US-53119208-A
Country	US
Kind code	B2
Filing date	Mar 12, 2008
Priority date	Mar 15, 2007
Publication date	Apr 4, 2017
Grant date	Apr 4, 2017

Abstract

Anti-fatigue agents containing dioxabicyclo[3.3.0]octane derivatives such as sesamin which is an ingredient contained in sesame, as well as pharmaceutical compositions and physiologically functional foods that contain such anti-fatigue agents are disclosed. These compounds can safely be administered to humans and animals alike and hence allow for continued ingestion while proving effective in promoting an improvement of stamina, an increase of body strength, a relief of fatigue, and recovery from fatigue.

First claim

The invention claimed is:

1. A method for treating a fatigue in a subject comprising administering to the subject at least one dioxabicyclo[3.3.0]octane derivative that is represented by the following general formula (I)

where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 each independently represent a hydrogen atom, an alkyl group having 1-3 carbon atoms, or R 1 and R 2 and/or R 4 and R 5 , when taken together, represent a methylene group or an ethylene group, and n, m, and l represent 0 or 1, to treat the fatigue in the subject,
wherein the fatigue is mental fatigue, and
wherein the dioxabicyclo[3.3.0]octane derivative is sesamin and/or episesamin, and
wherein the dioxabicyclo[3.3.0]octane derivative is administered to said subject in an amount corresponding to 50 to 80 mg/kg in mice.

2. A method for reducing risk of developing a fatigue in a subject comprising administering to the subject at least one dioxabicyclo[3.3.0]octane derivative that is represented by the following general formula (I)

where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 each independently represent a hydrogen atom, an alkyl group having 1-3 carbon atoms, or R 1 and R 2 and/or R 4 and R 5 , when taken together, represent a methylene group or an ethylene group, and n, m, and l represent 0 or 1, to reduce risk of developing the fatigue in the subject,
wherein the fatigue is mental fatigue, and
wherein the dioxabicyclo[3.3.0]octane derivative is sesamin and/or episesamin, and
wherein the dioxabicyclo[3.3.0]octane derivative is administered to the subject in an amount corresponding to 50 to 80 mg/kg in mice.

3. A method for promoting recovery from fatigue in a subject comprising administering to the subject at least one dioxabicyclo[3.3.0]octane derivative that is represented by the following general formula (I)

where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 each independently represent a hydrogen atom, an alkyl group having 1-3 carbon atoms, or R 1 and R 2 and/or R 4 and R 5 , when taken together, represent a methylene group or an ethylene group, and n, m, and l represent 0 or 1, to promote recovery from fatigue in the subject,
wherein the fatigue is mental fatigue, and
wherein the dioxabicyclo[3.3.0]octane derivative is sesamin and/or episesamin, and
wherein the dioxabicyclo[3.3.0]octane derivative is administered to the subject in an amount corresponding to 50 to 80 mg/kg in mice.

4. A method for reducing a possibility in a subject of suffering from fatigue comprising administering to the subject at least one dioxabicyclo[3.3.0]octane derivative that is represented by the following general formula (I)

where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 each independently represent a hydrogen atom, an alkyl group having 1-3 carbon atoms, or R 1 and R 2 and/or R 4 and R 5 , when taken together, represent a methylene group or an ethylene group, and n, m, and l represent 0 or 1, to reduce a possibility in the subject of suffering from fatigue,
wherein the fatigue is mental fatigue, and
wherein the dioxabicyclo[3.3.0]octane derivative is sesamin and/or episesamin, and
wherein the dioxabicyclo[3.3.0]octane derivative is administered to the subject in an amount corresponding to 50 to 80 mg/kg in mice.

5. A method for ameliorating ketosis in a subject comprising administering to the subject at least one dioxabicyclo[3.3.0]octane derivative that is represented by the following general formula (I)

where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 each independently represent a hydrogen atom, an alkyl group having 1-3 carbon atoms, or R 1 and R 2 and/or R 4 and R 5 , when taken together, represent a methylene group or an ethylene group, and n, m, and l represent 0 or 1, to ameliorate ketosis in the subject,
wherein the dioxabicyclo[3.3.0]octane derivative is sesamin and/or episesamin, and
wherein the dioxabicyclo[3.3.0]octane derivative is administered to the subject in an amount corresponding to 50 to 80 mg/kg in mice.

6. The method according to claim 1 , wherein the fatigue comprises feelings of weariness (tiredness), malaise (lassitude), a sleep disorder, or lowered motivation.

7. The method according to claim 2 , wherein the fatigue comprises feelings of weariness (tiredness), malaise (lassitude), a sleep disorder, or lowered motivation.

8. The method according to claim 3 , wherein the fatigue comprises feelings of weariness (tiredness), malaise (lassitude), a sleep disorder, or lowered motivation.

9. The method according to claim 4 , wherein the fatigue comprises feelings of weariness (tiredness), malaise (lassitude), a sleep disorder, or lowered motivation.

Assignees

• Ono Yoshiko
• Saito Kayo
• Tateishi Norifumi
• Maeda Akifumi
• Suntory Holdings Ltd

Inventors

• Ono Yoshiko
• Saito Kayo
• Tateishi Norifumi
• Maeda Akifumi

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/26

  Psychostimulants, e.g. nicotine, cocaine · CPC title

• A61P3/02

  Nutrients, e.g. vitamins, minerals · CPC title

• A23L33/10

  using additives (addition of substantially indigestible substances A23L33/21) · CPC title

• A23K20/111 Primary

  Aromatic compounds · CPC title